The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...

Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes This retrospective analysis included patients with ...

Researchers from the University of Washington and the University of Utah observed the DNA difference by analyzing fragments derived from human glioblastoma and hepatocellular carcinoma cells ...

What information could patients and providers learn from DNA found in a blood sample? An expert sat down with CURE to discuss ctDNA misconceptions. For patients with cancer, circulating tumor DNA ...

ctDNA can predict breast cancer relapse up to 38 months before clinical signs, with 88.2% accuracy in relapsed patients. Presence of ctDNA is linked to shorter relapse-free and overall survival, ...

This study is led by Prof. Luo Huiyan and Prof. Xu Ruihua (Department of Medical Oncology, Sun Yat Sen University Cancer Center). Colorectal adenomas (CRAs) represent precancerous lesions that precede ...

MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.

A new study suggests that a single blood sample could soon detect multiple cancers, including liver, stomach, and lung cancer, and other diseases by measuring the blood for DNA fragments.